Another phase II study in R/R IDH2-mutated AML patients has demonstrated a CR rate of 53% when utilizing azacitidine and enasidenib, compared to 12% with azacitidine alone (DiNardo et al., 2021), which significantly improved therapeutic effect. This evidence concerns the gene IDH2 and acute myeloid leukemia.